Arterial, portal, or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma. Review uri icon

Overview

abstract

  • Hepatic metastases from colorectal carcinoma are common and may be resected for cure. The response of liver metastases to systemic chemotherapy is low. In contrast, hepatic arterial chemotherapy produces higher response rates than systemic chemotherapy, but randomized trials have not definitely proved a survival advantage because they allowed cross over. Most adjuvant portal vein chemotherapy studies have shown a survival advantage over the control group, but it is not clear whether this benefit is from the portal vein therapy or from immediate postoperative chemotherapy, since there is rarely a reduction in liver metastases. We describe the results of systemic, hepatic artery infusion, and portal therapy for patients with liver metastases of colorectal carcinoma.

publication date

  • January 1, 1999

Research

keywords

  • Adenocarcinoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Colorectal Neoplasms
  • Liver Neoplasms

Identity

Scopus Document Identifier

  • 0032601767

Digital Object Identifier (DOI)

  • 10.1007/s005340050082

PubMed ID

  • 10436236

Additional Document Info

volume

  • 6

issue

  • 1